2-Cyano-5-Flurobenzyl Bromide CAS 421552-12-7 Purity ≥99.0% (HPLC) Trelagliptin Succinate Intermediate Factory
Commercial Supply Trelagliptin Succinate Related Intermediates:
6-Chloro-3-Methyluracil CAS 4318-56-3
2-Cyano-5-Flurobenzyl Bromide CAS 421552-12-7
(R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4
Trelagliptin Succinate Intermediate-int D CAS 865759-24-6
Trelagliptin Succinate CAS 1029877-94-8
Please contact: alvin@ruifuchem.com
| Chemical Name | 2-Cyano-5-Flurobenzyl Bromide |
| Synonyms | 2-(Bromomethyl)-4-Fluorobenzonitrile |
| CAS Number | 421552-12-7 |
| CAT Number | RF-PI143 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C8H5BrFN |
| Molecular Weight | 214.03 |
| Melting Point | 67.0 to 71.0℃ |
| Sensitive | Moisture Sensitive |
| Solubility | Soluble in Methanol |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-Yellow Powder |
| Purity / Analysis Method | ≥99.0% (HPLC) |
| Moisture (K.F) | ≤0.50% |
| Residue on Ignition | ≤0.30% |
| Single Impurity | ≤0.50% |
| Total Impurities | ≤1.00% |
| 1 H NMR Spectrum | Consistent With Structure |
| Test Standard | Enterprise Standard |
| Usage | Trelagliptin Succinate (CAS: 1029877-94-8) Intermediate |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 2-Cyano-5-Flurobenzyl Bromide (CAS: 421552-12-7) with high quality, widely used in organic synthesis, synthesis of pharmaceutical intermediates and active pharmaceutical ingredient (API) synthesis. 2-Cyano-5-Flurobenzyl Bromide can be used in the synthesis of Trelagliptin Succinate (CAS: 1029877-94-8). Trelagliptin Succinate is a selective, long acting dipeptidyl peptidase-4 (DPP-4) inhibitor. An antidiabetic agent. Orally active DPP-4 inhibitor that produces clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. Trelagliptin Succinate was approved for use in Japan in March 2015.
